4023-00-1

Basic information

• Product Name: Praxadine
• Synonyms: PYRAZOL-1-CARBOXAMIDINE;Unii-12L58gx4as;pyrazole-1-carboximidamide
• CAS NO: 4023-00-1
• Molecular Formula: C₄H₆N₄
• Molecular Weight: 146.58
• Mol File: 4023-00-1.mol

Chemical Properties

• Melting Point: 97-101 °C
• Boiling Point: 230.4°C at 760 mmHg
• Flash Point: 93.1°C
• Appearance: /
• Density: 1.42g/cm³
• Vapor Pressure: 0.066mmHg at 25°C
• Refractive Index: 1.683
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 7.53±0.49(Predicted)
• CAS DataBase Reference: Praxadine(CAS DataBase Reference)
• NIST Chemistry Reference: Praxadine(4023-00-1)
• EPA Substance Registry System: Praxadine(4023-00-1)

Safety Data

• Hazardous Substances Data: 4023-00-1(Hazardous Substances Data)

Usage

Uses

Used in Dermatological Applications:
Praxadine is used as a topical treatment for various skin conditions, including insect bites, rashes, and minor skin irritations. It is applied directly to the affected area in the form of creams, lotions, or ointments to provide fast-acting relief from itching, burning, and discomfort.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Praxadine is utilized as a medication for the management of dermatological issues. Its formulation with pramoxine and tannic acid allows for a dual-action approach to alleviate symptoms and promote skin health. The availability of Praxadine in various topical forms makes it a versatile option for healthcare professionals and patients seeking relief from skin-related discomfort.

InChI:InChI=1/C4H6N4/c5-4(6)8-3-1-2-7-8/h1-3H,(H3,5,6)

Upstream product

• 288-13-1 NH-pyrazole 
• 420-04-2 CYANAMID 

Downstream Products

• 152120-61-1 tert-butyl (1H-pyrazol-1-ylcarbonoimidoyl)carbamate 
• 152120-62-2 (N)-benzyloxycarbonyl-1H-pyrazole-1-carboxamidine 
• 959793-10-3 benzyl 4-carbamimidamidopiperidine-1-carboxylate 
• 712320-66-6 methyl 4-(4-fluorophenyl)-6-isopropyl-2-(1-pyrazolyl)-1,6-dihydropyrimidine-5-carboxylate 
• 152120-54-2 N,N'-bis( tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine 
• 49755-46-6 pyrrolidine-1-carboximidamide hydrochloride 
• 1037078-65-1 4-[4-(2-fluoro-ethoxy)-phenyl]-piperazine-1-carboxamidine 
• 1037078-64-0 4-(3-(fluoromethyl)phenyl)piperazine-1-carboximidamide 
• 1046859-47-5 2-amino-4-(4-bromo-2-chloro-5-methoxyphenyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboximidamide 
• 1380429-40-2 N-[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]-N-methylguanidine 

Relevant articles and documents

Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase

PRC2 is a multisubunit methyltransferase involved in epigenetic regulation of early embryonic development and cell growth. The catalytic subunit EZH2 methylates primarily lysine 27 of histone H3, leading to chromatin compaction and repression of tumor suppressor genes. Inhibiting this activity by small molecules targeting EZH2 was shown to result in antitumor efficacy. Here, we describe the optimization of a chemical series representing a new class of PRC2 inhibitors which acts allosterically via the trimethyllysine pocket of the noncatalytic EED subunit. Deconstruction of a larger and complex screening hit to a simple fragment-sized molecule followed by structure-guided regrowth and careful property modulation were employed to yield compounds which achieve submicromolar inhibition in functional assays and cellular activity. The resulting molecules can serve as a simplified entry point for lead optimization and can be utilized to study this new mechanism of PRC2 inhibition and the associated biology in detail.

Non-peptide GnRH agents, methods and intermediates for their preparation

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.